TM6SF2 acts at ER membrane contact sites to enable RAB7-dependent endolysosomal VLDL secretion and maintain Golgi structure
TM6SF2 E167K predisposes to hepatic steatosis and progression to inflammation, fibrosis, and cancer.
TM6SF2 E167K predisposes to hepatic steatosis and progression to inflammation, fibrosis, and cancer.